Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma
BackgroundTo date, there is no treatment consensus on mucosa-associated lymphoid tissue (MALT) derived primary pulmonary lymphoma (PPL).MethodsWe identified patients with early-stage MALT-type PPL from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program database. The...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.965727/full |
| _version_ | 1811339147735990272 |
|---|---|
| author | Huahang Lin Huahang Lin Ke Zhou Ke Zhou Zhiyu Peng Zhiyu Peng Linchuan Liang Linchuan Liang Jie Cao Jie Cao Jiandong Mei Jiandong Mei |
| author_facet | Huahang Lin Huahang Lin Ke Zhou Ke Zhou Zhiyu Peng Zhiyu Peng Linchuan Liang Linchuan Liang Jie Cao Jie Cao Jiandong Mei Jiandong Mei |
| author_sort | Huahang Lin |
| collection | DOAJ |
| description | BackgroundTo date, there is no treatment consensus on mucosa-associated lymphoid tissue (MALT) derived primary pulmonary lymphoma (PPL).MethodsWe identified patients with early-stage MALT-type PPL from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program database. The patients were divided into four groups according to treatment modalities: None of surgery or chemotherapy (None) group, Surgery alone group, Chemotherapy alone (Chemo alone) group, and Surgery plus chemotherapy (Surgery + chemo) group. Overall survival (OS) and cancer-specific survival (CSS) were study endpoints. We performed Cox regression analyses, propensity score-matched analyses (PSM) and Kaplan-Meier (KM) survival curves to compare the survival among different groups.ResultsA total of 953 patients were included in our analysis with 302, 403, 175, and 73 cases in the None, Surgery alone, Chemo alone, and Surgery + chemo groups, respectively. In this cohort, the estimated 3-year, 5-year and 10-year OS rates were 86.95%, 78.91%, and 55.89%, respectively. Meanwhile, the estimated 3-year, 5-year and 10-year CSS rates were 96.71%, 93.73%, and 86.84%, respectively. Multivariate Cox regression analyses demonstrated that increasing age, tumors located in the lower lobe, and stage II were significant predictors of poorer OS while increasing age and tumors located in the bilateral lungs were associated with lower CSS. After PSM analyses, the KM survival curves showed no significant differences in OS or CSS among the four groups.ConclusionEarly-stage MALT-type PPL is indolent in nature. Neither surgery, chemotherapy nor a combination of surgery and chemotherapy can improve OS and CSS, suggesting that “watch and wait” may be a reasonable alternative. |
| first_indexed | 2024-04-13T18:21:01Z |
| format | Article |
| id | doaj.art-b2771838f3104d60b97decdb1aa450da |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T18:21:01Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b2771838f3104d60b97decdb1aa450da2022-12-22T02:35:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.965727965727Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphomaHuahang Lin0Huahang Lin1Ke Zhou2Ke Zhou3Zhiyu Peng4Zhiyu Peng5Linchuan Liang6Linchuan Liang7Jie Cao8Jie Cao9Jiandong Mei10Jiandong Mei11Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, ChinaWestern China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, ChinaBackgroundTo date, there is no treatment consensus on mucosa-associated lymphoid tissue (MALT) derived primary pulmonary lymphoma (PPL).MethodsWe identified patients with early-stage MALT-type PPL from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program database. The patients were divided into four groups according to treatment modalities: None of surgery or chemotherapy (None) group, Surgery alone group, Chemotherapy alone (Chemo alone) group, and Surgery plus chemotherapy (Surgery + chemo) group. Overall survival (OS) and cancer-specific survival (CSS) were study endpoints. We performed Cox regression analyses, propensity score-matched analyses (PSM) and Kaplan-Meier (KM) survival curves to compare the survival among different groups.ResultsA total of 953 patients were included in our analysis with 302, 403, 175, and 73 cases in the None, Surgery alone, Chemo alone, and Surgery + chemo groups, respectively. In this cohort, the estimated 3-year, 5-year and 10-year OS rates were 86.95%, 78.91%, and 55.89%, respectively. Meanwhile, the estimated 3-year, 5-year and 10-year CSS rates were 96.71%, 93.73%, and 86.84%, respectively. Multivariate Cox regression analyses demonstrated that increasing age, tumors located in the lower lobe, and stage II were significant predictors of poorer OS while increasing age and tumors located in the bilateral lungs were associated with lower CSS. After PSM analyses, the KM survival curves showed no significant differences in OS or CSS among the four groups.ConclusionEarly-stage MALT-type PPL is indolent in nature. Neither surgery, chemotherapy nor a combination of surgery and chemotherapy can improve OS and CSS, suggesting that “watch and wait” may be a reasonable alternative.https://www.frontiersin.org/articles/10.3389/fonc.2022.965727/fullearly-stagemucosa-associated lymphoid tissueprimary pulmonary lymphomapropensity score-matching analysissurvivaltreatment modalities |
| spellingShingle | Huahang Lin Huahang Lin Ke Zhou Ke Zhou Zhiyu Peng Zhiyu Peng Linchuan Liang Linchuan Liang Jie Cao Jie Cao Jiandong Mei Jiandong Mei Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma Frontiers in Oncology early-stage mucosa-associated lymphoid tissue primary pulmonary lymphoma propensity score-matching analysis survival treatment modalities |
| title | Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma |
| title_full | Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma |
| title_fullStr | Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma |
| title_full_unstemmed | Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma |
| title_short | Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma |
| title_sort | surgery and chemotherapy cannot improve the survival of patients with early stage mucosa associated lymphoid tissue derived primary pulmonary lymphoma |
| topic | early-stage mucosa-associated lymphoid tissue primary pulmonary lymphoma propensity score-matching analysis survival treatment modalities |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.965727/full |
| work_keys_str_mv | AT huahanglin surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT huahanglin surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT kezhou surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT kezhou surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT zhiyupeng surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT zhiyupeng surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT linchuanliang surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT linchuanliang surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT jiecao surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT jiecao surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT jiandongmei surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma AT jiandongmei surgeryandchemotherapycannotimprovethesurvivalofpatientswithearlystagemucosaassociatedlymphoidtissuederivedprimarypulmonarylymphoma |